# Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

> **NCT00596791** · PHASE3 · COMPLETED · sponsor: **Santen Oy** · enrollment: 150 (estimated)

## Conditions studied

- Ocular Hypertension
- Open-Angle Glaucoma

## Interventions

- **DRUG:** tafluprost

## Key facts

- **NCT ID:** NCT00596791
- **Lead sponsor:** Santen Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2009-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00596791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00596791, "Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00596791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*